Articles tagged with Ovarian Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new experimental drug, 673A, targets and annihilates stem-like ovarian cancer cells that cause recurrence. The treatment, combined with chemotherapy, resulted in significantly greater survival rates in a mouse model of ovarian cancer.
Scientists at FAU create porous scaffolds using electrospinning to support ovarian follicle growth, showing promising results. The goal is to develop an ideal artificial ovary that mimics the natural environment for follicle maturity, potentially increasing fertility in cancer patients.
Researchers at the University of Kansas have developed a 'lab-on-a-chip' that can detect cancer in a minuscule amount of plasma, leading to timelier interventions and better outcomes for patients. The device uses a 3D nanoengineering method to mix and sense biological elements more efficiently, enabling faster and cheaper detection.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers developed AI software that predicts ovarian cancer prognosis and treatment effectiveness, outperforming existing methods by up to four times. The technology can stratify patients based on CT scan texture differences, enabling personalized medicine.
A two-year study found that out of 1919 women diagnosed with non-cancerous ovarian cysts, 20% had the cysts disappear on their own, and 80% either resolved or didn't require intervention. The risk of complications from surgical removal was lower than previously thought.
Losartan reduces extracellular matrix content and solid stress in ovarian tumors, increasing blood supply and drug delivery. The addition of losartan to chemotherapy agents could improve outcomes for patients with ovarian cancer.
A new study describes a novel approach to suppressing chemotherapy-induced tumor growth and recurrence in ovarian cancer. Researchers developed an anti-inflammatory drug called PTUPB that blocks the release of tumor-promoting chemicals by macrophages.
Researchers discovered that ovarian cancer cells colonize the omentum after being caught in DNA 'webs' extruded by immune cells. Inhibiting NET formation reduces metastasis in mice, suggesting a new approach to limit ovarian cancer spread. This study provides insights into improving ovarian cancer treatment.
A new blood test has been developed to detect early stage ovarian cancer using a bacterial toxin, with the test detecting significant levels of cancer glycan in over 90% of women with stage 1 ovarian cancer. The test also showed 100% accuracy for later stages of the disease and has potential for simple liquid biopsy monitoring.
A new photoacoustic imaging technique may help diagnose ovarian cancer at an early stage, improving survival rates. The technology uses transvaginal ultrasound and co-registered photoacoustic tomography to reveal information about tumor angiogenesis and blood oxygen saturation.
A new study of over 72,000 women found that simple ovarian cysts are normal and extremely common, with no association to a higher risk of ovarian cancer. Simple cysts should be considered normal findings in women of any age and can be safely ignored unless symptomatic.
Researchers at the University of Arizona are working on a disposable falloposcope to detect early-stage ovarian cancer. The device aims to reduce unnecessary procedures and improve patient outcomes by providing accurate screenings for high-risk women.
A University of Guelph study has found that opening up the blood vessels to an ovarian tumour can potentially improve the effectiveness of treatment. By creating a healthy blood supply, the tumour becomes more accessible to treatment, increasing success rates.
A phase 3 SOLO-1 trial found that olaparib maintenance therapy significantly improved progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation. The median PFS for those who received olaparib was approximately three years longer than the placebo group.
A study of 178 countries found a strong negative correlation between family size and cancer incidence, with larger families having a protective effect against various types of cancer. The protective effects are stronger for males than females, with non-reproduction-related cancers also being involved.
Researchers found that cancer cells from the fallopian tube affect ovary's chemical signaling, leading to increased norepinephrine levels, which drive cancer cell migration. This study highlights the importance of understanding chemistry in ovarian cancer development and treatment protocols.
Researchers discovered that mutations in the ARID1A gene lead to a molecular switch in the SWI/SNF protein complex, causing an increase in BCL2 expression and promoting tumor cell survival. Inhibiting BCL2 using a small molecule inhibitor kills ovarian cancer cells resistant to EZH2 inhibition.
A recent study published in JAMA Oncology found that low-dose aspirin (100mg or less) reduces the risk of ovarian cancer by 23% compared to non-users. Long-term heavy use of non-aspirin NSAIDs may increase this risk.
A new study found that daily low-dose aspirin use reduces the risk of ovarian cancer by 23 percent. In contrast, heavy use of non-aspirin NSAIDs increases the risk. The research analyzed data from over 200,000 women and confirms earlier findings about aspirin's role in reducing certain types of cancers.
A new cancer vaccine targeting HER2 has demonstrated clinical benefits in a phase I clinical trial, with six out of eleven evaluable patients experiencing improvements in their condition. The vaccine provided complete or partial responses and stable disease in some cases.
Researchers identified subtle epigenetic differences that explain why some ovarian cancer patients respond to PARPi drugs, while others do not. The study adds to a vital checklist for matching patients with the right therapy for their cancer.
A large study published by The BMJ found that newer combined oral contraceptives are associated with a reduced risk of ovarian cancer in young women. The positive effect strengthens with longer periods of use and persists for several years after stopping, providing reassurance for women.
Research teams identified CT45 as an independent prognostic factor for patients with high-grade serous ovarian cancer. High levels of CT45 were associated with extended disease-free survival, with patients living up to 7.5 years longer than those without sufficient CT45.
A new clinical trial suggests that combining CTLA4 targeted therapy with PD-1 targeted therapy may improve treatment outcomes for women with recurrent epithelial ovarian cancer. The trial found improved tumor response proportions and progression-free survival hazard rates in patients treated with the combination therapy.
Researchers have analyzed nearly 4,000 mutations in the BRCA1 gene, shedding light on its role in breast and ovarian cancer. The findings provide immediate benefits to patients with previously inconclusive genetic test results, enabling clinicians to better interpret variant of uncertain significance.
Researchers found that rapidly spreading ovarian cancer cells recruit CAFs to accelerate cancer proliferation and spread by enhancing energy sources. Blocking glycogen mobilization could be a therapeutic strategy for reducing tumor dissemination.
Researchers at UVA are developing a new antibody-based approach that combines targeting two receptors on ovarian cancer cells to increase its effectiveness. The approach has shown promising results in lab tests, with antibodies being more than 100 times more effective than existing therapies.
A study by University of Colorado Anschutz Medical Campus found that doctors with personal cancer experience are 17% more likely to recommend ovarian cancer screening to low-risk women, despite guidelines against it. This bias may be due to overestimating a patient's risk and prioritizing their experience over evidence-based guidelines.
A recent study found that only 8% of disabled or older women who qualified for Medicare received BRCA1 and BRCA2 testing between 2000 and 2014. Women with these mutations are at higher risk for developing second breast cancer and ovarian cancer, making timely testing crucial for informed decision-making.
Researchers found that normal fallopian tubes can contain pre-cancerous cells that escape and later progress to cancer in the pelvic or abdominal cavity. This 'precursor escape' concept may help explain why some women present with advanced ovarian cancer beyond the fallopian tubes.
Researchers at Johns Hopkins and Insilico Medicine discovered novel epigenetically silenced genes in ovarian cancer, including methylation of the GULP1 gene. GULP1 expression is associated with late-stage disease and poor overall survival, suggesting its potential as a biomarker.
Researchers have discovered that women with low-grade serous ovarian cancer and a BRAF gene mutation experience excellent responses to BRAF inhibitor treatments. This finding is encouraging for patients who may not respond to conventional chemotherapy.
Researchers at Rockefeller University have discovered the molecular means by which some cancers caused by BRCA1 mutations evade treatment by PARP inhibitors. The study challenges previous assumptions about the mechanics of these drugs and provides a foundation for advancements in PARP inhibitor therapy.
A large population study from Denmark found no causal association between assisted reproduction treatment and increased risk of ovarian cancer. Female infertility, rather than ovarian stimulation, was associated with an increased risk of ovarian cancer.
Researchers at Mayo Clinic have discovered how the DNA repair protein 53BP1 relocates to chromosomes to fix damage, using RNA molecules as an off/on switch. This finding could lead to new therapies for ovarian cancer by targeting a specific protein called TIRR.
A study of 99,654 individuals found that lifetime light alcohol drinkers had the lowest combined risk of mortality or developing cancer. The risk increased linearly with lifetime alcohol consumption, with heavy and very heavy drinkers facing significantly higher risks.
Researchers found a link between calcitriol and reduced ovarian cancer progression by blocking smad signaling in tumor cells and supportive fibroblasts. The study opens a new potential avenue for treating ovarian cancer, with calcitriol already FDA-approved for other uses.
The American Cancer Society report highlights a decline in ovarian cancer incidence and mortality rates in the US, with significant reductions seen among white populations. The strongest risk factor for ovarian cancer is a family history of breast or ovarian cancer, with BRCA1 and BRCA2 mutations accounting for nearly 40% of cases.
A population-based registry study confirms that secondary surgery can delay recurrence by two years and improve median overall survival by at least six years. The treatment model is centralized in Norway, which led to the favorable results, and may be adopted by other countries.
A cancer patient with advanced ovarian cancer responded well to treatment with hydroxychloroquine and quinacrine, initially prescribed for an autoimmune disease. The case report suggests that repurposing antimalarial drugs may improve cancer outcomes.
A phase II clinical trial suggests patients with aggressive pancreatic cancer who harbor BRCA mutations may benefit from rucaparib, a PARP inhibitor approved for ovarian cancer. The study found 32% of patients experienced a clinical benefit, including four patients with responses and two with stable disease.
Researchers have identified a key protein, MIP-1β, that enables ovarian cancer cells to spread through the peritoneal cavity by making mesothelial cells sticky. This discovery could lead to new therapies targeting this protein and its related adhesion protein P-selectin.
The study shows that ST1-ADC selectively inhibits tumor cell proliferation and induces tumor cell death in both in vitro and in vivo ovarian cancer models. The data provide promising results for the development of new therapeutic options to treat ovarian cancer.
PARP-1 levels are linked to targeted therapy resistance in ovarian cancer. Researchers have developed a method to image and measure PARP-1 using PET scans, which may predict efficacy and resistance to PARP inhibitors.
Researchers found that hemp extract slowed cell migration and reduced inflammation in ovarian cancer cells, suggesting a possible biological mechanism behind its anti-cancer effects. The study's results are comparable to or even better than current ovarian cancer drug Cisplatin, with potential for fewer side effects.
Researchers found tumors with PTEN loss are less likely to generate an immune response, suggesting PTEN levels can predict treatment outcome. The study's findings may improve personalized medicine for BRCA-deficient ovarian cancer patients.
Ludwig scientists present new data on cancers including colorectal, brain, breast, and ovarian cancer, as well as innovative clinical trials and novel approaches to cancer immunotherapy. The research focuses on mobilizing immunity against ovarian cancer and personalizing cancer treatment strategies.
A new personalized vaccine has shown promise in boosting immune responses and increasing survival rates in patients with advanced ovarian cancer. The vaccine combines different immunotherapies to better tackle the disease, which is often diagnosed at later stages and lacks curative treatment options.
The Rivkin Center awarded $1.185 million to ovarian cancer researchers worldwide, focusing on prevention and early detection, DNA repair, and novel therapies. This funding aims to improve early detection and discover new treatments for the deadly gynecological cancer.
Researchers developed a novel personalized vaccine made from tumor tissue and immune cells, inducing potent immune responses in patients with recurrent ovarian cancer. The vaccine showed promise in extending overall survival and improving progression-free survival.
The Translational Genomics Research Institute (TGen) will receive $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment, thanks to Colleen's Dream Foundation. The foundation has funded TGen in the past and has awarded over $1.2 million in grants to 27 institutions.
Researchers at Baylor College of Medicine have identified a key regulator of a cellular pathway that selectively targets mutant p53-R175H proteins, which promote ovarian cancer growth. The study suggests designing drugs directed at this regulator might lead to better ways to control cancer growth.
Researchers at The Wistar Institute have found that HDAC inhibitors can suppress proliferation and induce programmed cell death in ovarian cancer cells with ARID1A gene mutations. This new treatment approach has therapeutic potential, slowing tumor growth and improving survival rates in mouse models.
A new study from Virginia Tech found that fluid shear stress causes cancerous cells to become more aggressive and benign cells to exhibit traits of cancer. This discovery could lead to the development of a predictor for ovarian cancer, enabling earlier diagnosis and potentially saving thousands of lives.
Researchers developed a new screening test for endometrial and ovarian cancers using cervical fluid samples from routine Pap tests. The test, called PapSEEK, detected cancer cells in 81% of endometrial and 33% of ovarian cancers, with improved sensitivity when using different sampling methods.
A TGen-led study found that ponatinib significantly delays tumor growth and reduces tumor volume in SCCOHT, suggesting it should be tested for use in clinical trials. The rare form of ovarian cancer has a dismal two-year survival rate of less than 35 percent and affects young women and girls.
A new mutation on the X-chromosome has been identified as a potential contributor to earlier onset ovarian cancer in women. The study also found an association between this mutation and higher rates of prostate cancer in fathers and sons.
The US Preventive Services Task Force recommends against screening for ovarian cancer in women without symptoms and at low risk. The task force found that the harms of screening, including unnecessary surgery, outweigh its benefits.
A study found that screening the general population for cancer genes is cost-effective, preventing more breast and ovarian cancers. This approach could lead to thousands fewer cases of these cancers, particularly among women over 30.